Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Breckenridge Pharmaceutical, Inc |
| NDC | 51991-747-90 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. |
| Recalling firm | Breckenridge Pharmaceutical, Inc |
| Distribution | Nationwide in the US |
| Quantity | 163,883 bottles |
| Recall initiated | 2024-12-06 |
| Report date | 2025-01-01 |
| Recall completed | — |
| Recall number | D-0161-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berlin CT United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗